Drug major Ranbaxy Laboratories today said its subsidiary Ranbaxy Australia Pty Ltd has launched

RELATED ARTICLES Ranbaxy Q1 net zooms four-fold at Rs 1,247 cr Ranbaxy reappoints Arun Sawhney as CEO & MD for 5 years M&M gears up to launch XUV500 in Italy, Australia, Chile

generic Atorvastatin tablets, used for reducing cholesterol, in the Australian market.

The company's subsidiary RAPL has launched Atorvastatin tablets in the strengths of 10mg, 20mg, 40mg and 80mg in the Australian market after receiving approval from the regulatory authority in Australia, Therapeutic Goods Administration, Ranbaxy Laboratories said in a statement.

The product has been introduced under the brand name 'Trovas' and will be available in bottles and blister packs, through retail pharmacy chains, it added.

Commenting on the development, RAPL Managing Director Alex Evans said: "Ranbaxy is privileged to be the first generic company in Australia to introduce Atorvastatin under the brand name, 'Trovas'."

Atorvastatin is the most prescribed statin in Australia and according to IMS its current market size USD 680 mn, Ranbaxy said.

The company entered the Australian market in November 2006 and primarily has a portfolio of products covering CNS, CVS, gastro and anti-infectives, it added.

Shares of Ranbaxy Laboratories were quoted at Rs 451.85 on the BSE in afternoon trade, up 0.85 per cent from previous close.